Kindred Biosciences, Inc. (KIN) EPS Estimated At $-0.38

April 17, 2018 - By Clifton Ray

Kindred Biosciences, Inc. (NASDAQ:KIN) LogoInvestors sentiment decreased to 0.93 in 2017 Q4. Its down 1.31, from 2.24 in 2017Q3. It worsened, as 12 investors sold Kindred Biosciences, Inc. shares while 16 reduced holdings. 8 funds opened positions while 18 raised stakes. 17.44 million shares or 4.61% less from 18.28 million shares in 2017Q3 were reported.
Northern Corporation reported 262,160 shares. Schwab Charles Inv Mngmt reported 42,100 shares. Deutsche Financial Bank Ag has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Citigroup Inc has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Moreover, Ny State Common Retirement Fund has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 228,964 shares. Legal And General Group Plc holds 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 4,693 shares. Group One Trading L P has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Federated Invsts Pa has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). 92,274 are held by Granite Ptnrs Llc. Renaissance Tech Ltd, a New York-based fund reported 727,063 shares. Granahan Inv Ma holds 0.09% or 126,518 shares in its portfolio. Bnp Paribas Arbitrage Sa holds 7,384 shares. American Intll Gp reported 16,941 shares. C M Bidwell & Assocs Ltd invested in 25,310 shares. Manufacturers Life The reported 22,105 shares.

Since January 2, 2018, it had 0 insider buys, and 4 selling transactions for $254,552 activity. Chin Richard sold $167,800 worth of stock.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.38 EPS on May, 2.They anticipate $0.08 EPS change or 26.67 % from last quarter’s $-0.3 EPS. After having $-0.35 EPS previously, Kindred Biosciences, Inc.’s analysts see 8.57 % EPS growth. The stock increased 0.54% or $0.05 during the last trading session, reaching $9.3. About 50,350 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 18.31% since April 17, 2017 and is uptrending. It has outperformed by 6.76% the S&P500.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 3 analysts covering Kindred Biosciences (NASDAQ:KIN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Kindred Biosciences had 5 analyst reports since November 17, 2017 according to SRatingsIntel. H.C. Wainwright maintained the shares of KIN in report on Friday, March 2 with “Buy” rating. On Wednesday, December 27 the stock rating was initiated by C.L. King with “Hold”. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) earned “Buy” rating by FBR Capital on Monday, February 26.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $262.16 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: